RevMed Q3 net loss $156M; Phase 3 PDAC trial started, RMC-9805 initial data

Revolution Medicines, Inc.

2024-Q3 EPS reported -$2.45

Net loss of $156.3M for Q3 2024 vs. $108.4M in Q3 2023; R&D expenses rose to $151.8M.
Cash, equivalents and securities were $1.55B as of Sept 30, 2024; funding projected into 2027.
Phase 3 RASolute 302 trial of RMC-6236 in metastatic PDAC dosed first patient; data event-driven.
Initial RMC-9805 (KRAS G12D inhibitor) data show encouraging safety and antitumor activity; 1200 mg once daily candidate Phase 2 dose.
FY 2024 GAAP net loss guidance reiterated at $560M-600M; NSCLC and combination data due in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.